

MEDICAMEN Biotech Limited



Regd. Office :
1506, Chiranjiv Tower,
43, Nehru Place, New Delhi-110019
CIN No. : L74899DL1993PLC056594

Tel. : 011 - 47589500, 41608929
Tel. : 011 - 21800032
Fax : 011 - 26213081
Web : www.medicamen.com

Ref: STEX/RESULTS/2018-19

Date: 05.07.2018

BSE Limited
Department of Corporate Services-Listing
PJ Towers, Dalal Street
Mumbai- 400001

Company No.: 531146

Sub. : Revised Financial Result for the Year ended 2018


Dear Sir,

This is to inform you that revised financial results for the year ended on March 2018 along with reconciliation of Net Profit/ losses and Equity Shares as previously reported on account of transition from the previous Indian GAAP to IND-AS for year ended March 2017 now been enclosed for your reference.

This is for your information and records.

Thanking You.

Yours faithfully,
For Medicamen Biotech Limited


Parul Choudhary
Company Secretary
ACS-44157



MEDICAMEN BIOTECH LIMITED
1506, Chiranjiv Tower, 43, Nehru Place, New Delhi-110019
CIN : L74899DL 1993PLC056594

Audited Standalone Financial Results for the quarter and year ended on 31st March 2018

PART I

Rupees in Lacs (Except per Share data)

Particulars	Quarter Ended			Year Ended	
	3 Months Ended 31/03/2018 Audited	Preceding 3 Months Ended 31/12/2017 Unaudited	Corresponding 3 Months Ended 31/03/2017 Audited	Year Ended 31/03/2018 Audited	Year Ended 31/03/2017 Audited
1 Income from operations					
(a) Net Sales/Income from operations (Net of excise duty)	2,930.08	2,829.29	2,228.35	11,150.72	8,245.57
(b) Other Income	99.83	(21.55)	(32.85)	188.79	30.66
(c) Total Revenue	3,029.91	2,807.74	2,195.50	11,339.51	8,276.23
2 Expenses					
a) Cost of Material Consumed	1,864.82	1,763.39	1,381.60	6,878.24	4,777.75
b) Purchase of Stock-in-Trade	-	-	10.39	0.05	44.10
c) Changes in inventory of Finished Goods and Work in Progress	50.07	(158.22)	(83.18)	(113.07)	99.07
d) Employees Benefits Expenses	187.17	243.70	231.16	905.30	665.26
e) Finance Cost	51.05	74.35	85.56	240.81	303.20
f) Depreciation and Amortisation Expenses	49.88	56.32	49.83	205.79	192.23
g) Other expenses	449.80	487.55	362.48	1,832.38	1,558.74
Total Expenses	2,652.79	2,467.09	2,037.84	9,949.51	7,640.36
3 Profit/(Loss) before Exceptional Items & Tax (1-2)	377.12	340.65	157.67	1,390.00	635.87
4 Exceptional Items (Commercial Tax Expenses Related to Earlier Year)	-	-	-	-	-
5 Profit/(Loss) before Extra Ordinary Items & Tax (3-4)	377.12	340.65	157.67	1,390.00	635.87
6 Tax Expenses					
Current Year	195.26	74.05	32.15	401.78	129.65
Deferred Tax Liability	(4.38)	(17.40)	10.46	(23.05)	(9.78)
Total Tax Expenses	190.88	56.65	42.61	378.73	119.87
7 Net Profit/Loss for the period (5-6)	186.24	284.00	115.06	1,011.27	516.01
8 Other Comprehensive Income					
Item that will not be reclassified to Profit & Loss					
Total Comprehensive income Net of Tax	186.24	284.00	115.06	1,011.27	516.01
9 Total Comprehensive income for the Period (7+8)	186.24	284.00	115.06	1,011.27	516.01
10 Paid-up equity share capital (Rs. 10/- per share)	1,170.00	1,137.60	1,051.86	1,170.00	1,051.86
11 Earning Per Share (Rs.)					
(a) Basic	1.66	2.49	1.10	9.03	4.95
(b) Diluted	1.66	2.49	1.10	9.03	4.95

NOTES :

- The above results after being reviewed by the Audit Committee have been taken on record by the Board at its Meeting held on 30th, May, 2018.
- The figures are regrouped in previous year also, wherever considered necessary.
- The company operates only in one business segment, viz. Pharmaceuticals Formulations, hence segment reporting is not applicable.
- The Earning Per Share has been calculated as per AS-20.
- Auditor's Report has been carried out by the Statutory Auditors for the above period.
- Reconciliation of Net profit/(losses) as previously reported on account of transition from the previous Indian-GAAP to Ind-AS for the Quarter and year ended March 31, 2017.

Particulars	Quarter Ended March 31, 2017	Year Ended March 31, 2017
Profit/(Loss) as per previous GAAP	115.06	516.01
Adjustment in relation to IND-AS	-	-
Total Comprehensive Income as per Ind-As	115.06	516.01

- Reconciliation of Equity Share as previously reported on account of transition from Previous India-GAAP to Ind-AS for the year ended March 31, 2017.

Particulars	Year Ended March 31, 2017
Balance As per Previous GAAP	2,678.09
Adjustment in relation to IND-AS	-
Equity Balance as per Ind-AS	2,678.09

For & on behalf of Board of Directors
Medicamen Biotech Limited

R. Bishnoi
(Rahul Bishnoi)
Chairman

Place : Delhi
Dated : 30.05.2018



STATEMENT OF ASSETS & LIABILITIES			
Particulars	As at		
	March 31, 2018 Audited	March 31, 2017 Audited	
A ASSETS			
1 Non-current assets			
(a) Property, Plant and Equipment	2,501.87	1,902.97	
(b) Intangible assets	31.69	2.18	
(c) Capital work-in-progress	27.86	44.85	
(d) Financial Assets : Loans and advances	56.81	52.03	
(e) Other Non-current assets	38.26	-	
Total Non-current Assets	2,656.49	2,002.03	
2 Current assets			
(a) Inventories	1,423.42	1,378.99	
(b) Financial Assets			
(i) Current investments	7.00	7.00	
(ii) Trade receivables	3,842.38	2,568.65	
(iii) Cash and Bank Balances	2,266.48	296.89	
(iv) Loans and advances	1,295.95	885.13	
(c) Other current assets	263.34	201.36	
Total current Assets	9,098.57	5,338.02	
Total Assets	11,755.06	7,340.05	
B EQUITY AND LIABILITIES			
1 Equity			
(a) Equity share capital	1,170.00	1,051.86	
(b) Other Equity	6,290.79	1,626.23	
Total Equity	7,460.79	2,678.09	
LIABILITIES			
2 Non-current Liabilities			
(a) Financial Liabilities : Borrowings	14.18	246.39	
(b) Provisions	117.92	84.52	
(c) Deferred Tax liabilities (Net)	41.36	64.40	
Total Non-current Liabilities	173.46	395.31	
3 Current Liabilities			
(a) Financial Liabilities			
(i) Borrowings	1,424.45	1,408.83	
(ii) Trade payables	2,180.00	2,230.65	
(b) Other current liabilities	86.60	481.23	
(c) Provisions	429.76	145.94	
	4,120.81	4,266.65	
Total Equity and Liabilities	11,755.06	7,340.05	

For & on behalf of Board of Directors
Medicamen Biotech Limited

R. Bishnoi
(Rahul Bishnoi)
Chairman

Place : Delhi
Dated : 30.05.2018

Tarun

